U.S. Markets closed

RepliCel Life Sciences Inc. (REPCF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.4128+0.0028 (+0.6829%)
At close: 3:39PM EDT
People also watch
Full screen
Previous Close0.4100
Bid0.0000 x
Ask0.0000 x
Day's Range0.3950 - 0.4269
52 Week Range0.3220 - 1.4600
Avg. Volume40,347
Market Cap7.69M
PE Ratio (TTM)-1.15
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • SmarterAnalyst2 months ago

    Exclusive Interview with RepliCel Life Sciences President and CEO Lee Buckler

    RepliCel Life Sciences Inc. (REPCF) (RP.V) is a biotech company looking not to just treat symptoms, but find cures. RepliCel may have the key, not just to rejuvenated skin and functioning tendons, but also a safe way to stop – and perhaps even reverse - hair loss. This week, I held an interview with President & CEO, Lee Buckler, who spoke with great passion of RepliCel's multi-course trajectory.

  • Zacks Small Cap Research4 months ago

    RepliCel (RP.V) Targeting Multiple Billion Dollar Markets With Autologous Cell Therapies

    RepliCel Life Sciences, Inc. (REPCF) (RP.V) is a regenerative medicine company focused on the use of autologous cell therapies for the treatment of cellular deficits. The company is targeting three potentially multi-billion dollar markets: regenerative hair growth, skin aging, and chronic tendinosis.

  • Zacks Small Cap Research6 months ago

    RepliCel (RP.V) Should Benefit From Renewed Investor Focus, Sweeping Legislation On Cell Therapy

    Cell therapy is hot again! On December 12, 2016, Bayer AG and Versant Ventures joined forces to launch a new stem cell therapy company called BlueRock Therapeutics. BlueRock is focused on breakthrough treatments based on latest stem cell technology.